Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $98.60 | Total: $493.00 |
| 1 | 10 | $83.52 | Total: $835.20 |
| 1 | 25 | $70.76 | Total: $1,769.00 |
| 1 | 50 | $60.32 | Total: $3,016.00 |
| 1 | 100 | $52.20 | Total: $5,220.00 |
Overview
Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively. Treprostinil diethanolamine contributes to the upregulation of cAMP, maintaining vascular homeostasis and causing vasodilation in human pulmonary arteries.
Chemical Properties
| Molecular Formula | C27H45NO7 |
| Molecular Weight | 495.65 |
| CAS Numbers | 830354-48-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(CCO)CCO.C(C[C@H](CCCCC)O)[C@@H]1[C@@]2([C@@](CC=3C(C2)=CC=CC3OCC(O)=O)(C[C@H]1O)[H])[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Whittle BJ, et, al. Binding and activity of the prostacyclin receptor [IP] agonists, treprostinil and iloprost, at human prostanoid receptors treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84[1] 68-75.